Schein P - Search Results

1

Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026].

Powles T, Paterson A, McCloskey E, Schein P, Scheffler B, Tidy A, Ashley S, Smith I, Ottestad L, Kanis J. Powles T, et al. Among authors: schein p. Breast Cancer Res. 2006;8(2):R13. doi: 10.1186/bcr1384. Epub 2006 Mar 15. Breast Cancer Res. 2006. PMID: 16542503 Free PMC article. Clinical Trial.

2

The role of hexamethylmelamine in the management of ovarian cancer.

Schein PS, Scheffler B, McCulloch W. Schein PS, et al. Cancer Treat Rev. 1991 Mar;18 Suppl A:67-75. doi: 10.1016/0305-7372(91)90026-v. Cancer Treat Rev. 1991. PMID: 1904311 Review.

3

New protective agents for bone marrow in cancer therapy.

McCulloch W, Scheffler BJ, Schein PS. McCulloch W, et al. Among authors: schein ps. Cancer Invest. 1991;9(3):279-87. doi: 10.3109/07357909109021325. Cancer Invest. 1991. PMID: 1655173 Review.

4

Amifostine-mediated protection of normal bone marrow from cytotoxic chemotherapy.

Capizzi RL, Scheffler BJ, Schein PS. Capizzi RL, et al. Among authors: schein ps. Cancer. 1993 Dec 1;72(11 Suppl):3495-501. doi: 10.1002/1097-0142(19931201)72:11+<3495::aid-cncr2820721617>3.0.co;2-b. Cancer. 1993. PMID: 8242582 Review.

5

Analysis of prognostic factors and survival in patients with ovarian cancer treated with second-line hexamethylmelamine (altretamine).

Manetta A, MacNeill C, Lyter JA, Scheffler B, Podczaski ES, Larson JE, Schein P. Manetta A, et al. Among authors: schein p. Cancer Treat Rev. 1991 Mar;18 Suppl A:23-9. doi: 10.1016/0305-7372(91)90021-q. Cancer Treat Rev. 1991. PMID: 1904305

6

Hexamethylmelamine as a single second-line agent in ovarian cancer.

Manetta A, MacNeill C, Lyter JA, Scheffler B, Podczaski ES, Larson JE, Schein P. Manetta A, et al. Among authors: schein p. Gynecol Oncol. 1990 Jan;36(1):93-6. doi: 10.1016/0090-8258(90)90115-2. Gynecol Oncol. 1990. PMID: 2104819

7

A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. International Collaborative Cancer Group.

Coombes RC, Schein PS, Chilvers CE, Wils J, Beretta G, Bliss JM, Rutten A, Amadori D, Cortes-Funes H, Villar-Grimalt A, et al. Coombes RC, et al. Among authors: schein ps. J Clin Oncol. 1990 Aug;8(8):1362-9. doi: 10.1200/JCO.1990.8.8.1362. J Clin Oncol. 1990. PMID: 2199622 Clinical Trial.

8

Esophageal carcinoma following irradiation for breast cancer.

Goffman TE, McKeen EA, Curtis RE, Schein PS. Goffman TE, et al. Among authors: schein ps. Cancer. 1983 Nov 15;52(10):1808-9. doi: 10.1002/1097-0142(19831115)52:10<1808::aid-cncr2820521008>3.0.co;2-w. Cancer. 1983. PMID: 6354415 Review.

9

Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer.

Poplin EA, LoRusso P, Lokich JJ, Gullo JJ, Leming PD, Schulz JJ, Veach SR, McCulloch W, Baker L, Schein P. Poplin EA, et al. Among authors: schein p. Cancer Chemother Pharmacol. 1994;33(5):415-9. doi: 10.1007/BF00686271. Cancer Chemother Pharmacol. 1994. PMID: 8306416 Clinical Trial.

10

WR-2721: a chemotherapy and radiation-protective agent.

Schein PS. Schein PS. Cancer Invest. 1990;8(2):265-6. doi: 10.3109/07357909009017579. Cancer Invest. 1990. PMID: 2169331 Clinical Trial. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

277 results

Search Page